Hot Features
Premium
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Rexahn Pharmaceuticals, Inc. (NYSE MKT:RNN), a clinical stage biopharmaceutical company developing best-in-class therapeutics for the treatment of cancer, today announced the release of an online publication describing preclinical results for Supinoxin(RX-5902) in the peer reviewed medical journal, Journal of Cellular Biochemistry.
In an article titled, “A Novel Anti-Cancer Agent, 1-(3,5-Dimethoxyphenyl)-4-[(6-fluoro-2-methoxyquinoxalin-3-yl)aminocarbonyl] piperazine (RX-5902), Interferes with β-Catenin Function through Y593 phospho-p68 RNA Helicase.” The article was coauthored by Dr. Zhi-Ren Liu of the Department of Biology, at Georgia State University, and Rexahn scientists.
In this study, Supinoxin was shown to directly bind to phosphorylated p68 and inhibit β-catenin dependent ATPase activity resulting in a decrease in expression of a number of cancer related downstream genes (oncogenes) such as c-Myc, cyclin-D1 and p-cJun. The expression of these oncogenes is a key step in the growth and proliferation of cancer cells. The ability of Supinoxin to disrupt the β-catenin/phosphorylated p68/oncogene pathway represents a novel mechanism for the inhibition of growth of human cancer cells.
Dr. Zhi-Ren Liu of the Department of Biology, Georgia State University and coauthor of this study, commented, “The ability of Supinoxin to directly bind to P-p68 and abolish the effects of P-p68 in upregulation of these oncogenes is very exciting. This novel pathway holds great promise for treatment of cancer patients.”
Peter D. Suzdak, Ph.D., Rexahn’s Chief Executive Officer, commented, “The specificity of this mechanism of action for cancer cells and the efficacy seen in multiple preclinical models utilizing human cancer cells continues to generate significant interest in Supinoxin. Once the current Phase I clinical trial is complete, we will provide an update on the safety, tolerability, dose-limiting toxicities, maximal tolerated dose (MTD), pharmacokinetics and preliminary anti-tumor effects seen with Supinoxin.”
